Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03834220
Previous Study | Return to List | Next Study

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03834220
Recruitment Status : Recruiting
First Posted : February 7, 2019
Last Update Posted : November 28, 2019
Sponsor:
Collaborators:
Caris Life Sciences
Optimal Research (Just In Time sites) - other USA study locations can be available on demand, please contact optimalcommunity@optimaljit.com
Information provided by (Responsible Party):
Debiopharm International SA

Brief Summary:
The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: Debio 1347 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3
Actual Study Start Date : March 1, 2019
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : August 31, 2022

Arm Intervention/treatment
Experimental: Debio 1347
Participants will receive Debio 1347 once daily from Day 1 to Day 28 in 28-Day cycles.
Drug: Debio 1347
80 milligrams (mg) dose of Debio 1347 orally once daily from Day 1 to Day 28 in 28-Day cycle.




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Up to 44 months ]

Secondary Outcome Measures :
  1. Duration of Response (DOR) [ Time Frame: Day 28 or end of Cycle (each cycle is 28 days) 2, 4, 6 followed by every 3 cycles (end of cycle) for up to 24 months or end of treatment or death due to any cause (up to 44 months) ]
  2. Disease Control Rate (DCR) [ Time Frame: Day 28 or end of Cycle (each cycle is 28 days) 2, 4, 6 followed by every 3 cycles (end of cycle) for up to 24 months or end of treatment (up to 44 months) ]
  3. Progression-Free Survival (PFS) [ Time Frame: Day 28 or end of Cycle (each cycle is 28 days) 2, 4, 6 followed by every 3 cycles (end of cycle) for up to 24 months or end of treatment or death due to any cause (up to 44 months) ]
  4. Overall Survival (OS) [ Time Frame: Up to 44 months ]
  5. Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 44 months ]
  6. Trough Concentration (Ctrough) of Debio 1347 [ Time Frame: Up to Cycle 2 (each cycle is 28 days) ]
  7. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCt) of Debio 1347 [ Time Frame: Up to Cycle 2 (each cycle is 28 days) ]
  8. Correlation of Debio 1347 plasma concentration and QTcF [ Time Frame: Up to 44 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cytologically or histologically confirmed advanced solid tumor
  • Radiographic progression on prior systemic therapy; prior localized therapy (i.e., radiation, ablation, embolization) is allowed provided radiographic progression out-of-field or in the treatment, field is shown
  • Locally-advanced (unresectable) or metastatic disease harboring an FGFR1-3 gene fusion/rearrangement potentially leading to a functional FGFR aberrant protein, identified through local and/or central molecular assay

Exclusion Criteria:

  • History of hypersensitivity to any of the excipients in the Debio 1347 formulation
  • History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes, lung nodules and asymptomatic vascular or cartilage/tendon calcifications
  • Administration of any investigational agent within 2 weeks prior to initial dosing with Debio 1347 (3 weeks for immune checkpoint inhibitors)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03834220


Contacts
Layout table for location contacts
Contact: Debiopharm International S.A +41 21 321 01 11 clinicaltrials@debiopharm.com

  Show 94 Study Locations
Sponsors and Collaborators
Debiopharm International SA
Caris Life Sciences
Optimal Research (Just In Time sites) - other USA study locations can be available on demand, please contact optimalcommunity@optimaljit.com

Additional Information:
Layout table for additonal information
Responsible Party: Debiopharm International SA
ClinicalTrials.gov Identifier: NCT03834220     History of Changes
Other Study ID Numbers: Debio 1347-201
2018-003584-53 ( EudraCT Number )
First Posted: February 7, 2019    Key Record Dates
Last Update Posted: November 28, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms